FdaApplication
NDA 210134
Identifiers
- fda_app_no: NDA210134
Properties
| Property | Value |
|---|---|
| applicant_name | AMPHASTAR PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2019-07-24 |
Revenue by product
BAQSIMI
| Period | Revenue |
|---|---|
| Q2 2026 | $0.1M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| BAQSIMI | GLUCAGON | 3MG | POWDER;NASAL |
1 product